Yes, patients can be on Brilinta (ticagrelor) and heparin simultaneously
Brilinta and unfractionated heparin are routinely used together in acute coronary syndrome patients undergoing percutaneous coronary intervention, with no clinically significant drug interactions and an acceptable safety profile when dosed appropriately. 123
Evidence Supporting Concurrent Use
Guideline Recommendations
The 2020 ESC Guidelines for acute coronary syndromes explicitly include unfractionated heparin (UFH) in treatment algorithms alongside P2Y12 inhibitors like ticagrelor 1. This represents standard practice in NSTE-ACS patients undergoing PCI, where dual antiplatelet therapy (aspirin + ticagrelor) is combined with procedural anticoagulation.
Pharmacological Compatibility
A dedicated pharmacokinetic/pharmacodynamic study demonstrated that:
- UFH co-administration had no significant effect on ticagrelor pharmacokinetics
- Only minimal reductions in platelet inhibition occurred (IPA max decreased by 3.8%, AUEC decreased by 6.8%) - these changes are not clinically significant 3
- Ticagrelor had no clinically significant effects on UFH's anticoagulant activity as measured by aPTT or ACT 3
Real-World Clinical Outcomes
Recent observational data from STEMI patients shows that early upstream administration of aspirin, ticagrelor, and UFH together was associated with:
- Greater pre-PCI TIMI flow (44.6% vs 18.5%)
- Less acute stent thrombosis (0.6% vs 2.6%)
- No increase in bleeding risk (BARC 2-5 bleeding: 1.9% vs 3.5%, p=0.18) 4
Bleeding Risk Management
Key Considerations
While both agents increase bleeding risk independently, their combination is manageable:
- The FDA label warns that ticagrelor increases bleeding risk, particularly when combined with anticoagulants 22
- However, this is an expected and acceptable risk in the acute coronary syndrome setting where thrombotic risk outweighs bleeding risk
- Recent pharmacovigilance data identified hemorrhagic signals when ticagrelor is combined with heparin or enoxaparin, but this reflects the known pharmacology rather than a contraindication 5
Practical Dosing Strategy
Based on recent evidence, consider:
- Lower heparin dosing (50 IU/kg) may reduce hemorrhagic complications compared to 70 IU/kg when used with ticagrelor-based DAPT 6
- Standard ticagrelor dosing: 180 mg loading dose, then 90 mg twice daily 1
- Aspirin: 150-300 mg loading dose, then 75-100 mg daily 1
Critical Laboratory Interaction Warning
Ticagrelor causes false-negative results in heparin-induced thrombocytopenia (HIT) functional assays (specifically the HIPA assay) due to P2Y12 receptor inhibition on donor platelets 227. This does NOT affect PF4 antibody testing for HIT.
Clinical implication: If you suspect HIT in a patient on ticagrelor:
- Inform the laboratory that the patient is taking ticagrelor
- Rely on PF4 antibody testing rather than functional assays
- Do not assume a negative functional assay rules out HIT 7
When to Avoid or Use Caution
Avoid this combination in:
- Patients with active pathological bleeding
- Recent intracranial hemorrhage or ischemic stroke
- Severe hepatic impairment (ticagrelor contraindication) 2
Use lower heparin doses in:
- Elderly patients
- Patients requiring multiple stents
- Those with baseline bleeding risk factors 6